January 2017 in “Clinical pharmacist” Long use of finasteride and dutasteride can cause long-term erection problems.
December 2016 in “Reactions Weekly” Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
September 2016 in “Reactions Weekly” Dutasteride and finasteride don't raise erectile dysfunction risk.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
January 2015 in “프로그램북(구 초록집)” This article reviews the impact of dutasteride on hair growth in androgenetic alopecia, finding it significantly increases hair count and width compared to finasteride and placebo, but reports no new results.
March 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
February 2014 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This review discusses a study on the efficacy and safety of different doses of dutasteride compared to placebo and finasteride in treating men with androgenetic alopecia and reports no new results.
March 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Dutasteride helps reduce male pattern hair loss, but may cause side effects like altered libido and erectile dysfunction.
March 2002 in “Hair transplant forum international” This article discusses the FDA approval of dutasteride for benign prostatic hypertrophy and explores its potential role in treating androgenetic alopecia but reports no new clinical findings.
August 2026 in “Mendeley Data” This review article systematically summarizes current knowledge on using hair follicle neural crest stem cells and their exosomes for repairing peripheral nerve injuries, focusing on the molecular mechanisms and potential applications. The dataset includes comparison tables and diagrams to visually present findings from existing research.
August 2026 in “Mendeley Data” This review systematically assembles recent insights into the use of hair follicle neural crest stem cells and their exosomes for peripheral nerve injury repair, highlighting molecular mechanisms and possible translational applications, with comprehensive tables and diagrams summarizing existing literature.
May 2026 in “Mendeley Data” In this review, the authors systematically summarize recent advances in using hair follicle neural crest stem cells and their exosomes for repairing peripheral nerve injuries, focusing on mechanisms and applications derived from existing literature, although it does not include primary experimental data.
January 2026 in “Mendeley Data” This study's dataset provides summary figures and tables reviewing recent advances in using hair follicle neural crest stem cells and their exosomes for repairing peripheral nerve injuries, focusing on their molecular mechanisms and potential clinical applications.
December 2023 in “Data in Brief” In this study, the researchers conducted tensile tests on individual curly human hair fibers sourced from a female donor and found distinct mechanical properties under various conditions, including different strain rates and temperatures, both dry and in saline immersion.
December 2021 in “INDIGO (University of Illinois at Chicago)” This study used single-cell RNA sequencing to characterize 19 distinct cell populations in sheep hair follicles, uncovering differentiation signatures and intercellular communication that may influence wool curvature and sheep breeding.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” This review discusses recent advancements in targeted therapies for vitiligo, highlighting the therapeutic potential of JAK inhibitors and mesenchymal stem cell-derived extracellular vesicles, and reports no new clinical results.
December 2021 in “Figshare” This review discusses recent advancements in targeted therapies for vitiligo, including JAK inhibitors and mesenchymal stem cells, and highlights the need for further research.
This study found that GPC1 is a key regulator of angiogenesis in human dermal microvascular endothelial cells, influenced by factors secreted by keratinocytes, and may be a target for alopecia treatment research.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” This study found that BBS7 is crucial for maintaining Sonic hedgehog signaling activity and periodontal ligament homeostasis, with changes in gene expression observed in occlusal hypofunctional PDL.
December 2021 in “Figshare” This study found that BBS7 is downregulated in occlusal hypofunctional periodontal ligament, suggesting it plays a crucial role in maintaining Shh signaling for PDL homeostasis.
December 2021 in “Figshare” This study found that downregulation of BBS7 in periodontal ligament cells was associated with reduced Sonic hedgehog signaling, which plays a crucial role in maintaining PDL homeostasis.
December 2021 in “Figshare” This study found that BBS7 expression is crucial for maintaining Sonic hedgehog signaling activity and periodontal ligament homeostasis, suggesting its downregulation in occlusal hypofunction affects cell migration and angiogenesis.
December 2021 in “Figshare” This study found that BBS7 is crucial for maintaining Shh signaling and periodontal ligament homeostasis, with occlusal hypofunction leading to its downregulation and impacting cell migration and angiogenesis.
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
February 2026 in “Frontiers in Medicine” This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.
This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” This article reviews current therapeutic strategies for frontal fibrosing alopecia and discusses the potential of oral dutasteride as a first-line treatment, emphasizing the need for more clinical trials.
June 2022 in “Journal of The European Academy of Dermatology and Venereology” This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.
August 2016 in “Journal of Investigative Dermatology” This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.
3 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Dermatology datasets need more diversity in skin tones and ethnic representation.